BNP Paribas Financial Markets’s PDS Biotechnology PDSB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $571 | Hold |
648
| – | – | ﹤0.01% | 5667 |
|
|
2026
Q1 | $392 | Hold |
648
| – | – | ﹤0.01% | 5563 |
|
|
2025
Q4 | $499 | Sell |
648
-488
| -43% | -$440 | ﹤0.01% | 5478 |
|
|
2025
Q3 | $1.15K | Sell |
1,136
-2
| -0.2% | -$2 | ﹤0.01% | 5225 |
|
|
2025
Q2 | $1.51K | Hold |
1,138
| – | – | ﹤0.01% | 5104 |
|
|
2025
Q1 | $1.35K | Sell |
1,138
-98
| -8% | -$139 | ﹤0.01% | 5030 |
|
|
2024
Q4 | $2.02K | Sell |
1,236
-41
| -3% | -$109 | ﹤0.01% | 5013 |
|
|
2024
Q3 | $4.88K | Sell |
1,277
-8,603
| -87% | -$28.7K | ﹤0.01% | 3845 |
|
|
2024
Q2 | $28.9K | Sell |
9,880
-4,243
| -30% | -$13.6K | ﹤0.01% | 3584 |
|
|
2024
Q1 | $55.9K | Buy |
14,123
+513
| +4% | +$2.64K | ﹤0.01% | 3560 |
|
|
2023
Q4 | $67.6K | Sell |
13,610
-3,975
| -23% | -$19.8K | ﹤0.01% | 3502 |
|
|
2023
Q3 | $88.8K | Buy |
17,585
+10,290
| +141% | +$56.4K | ﹤0.01% | 3356 |
|
|
2023
Q2 | $36.7K | Buy |
+7,295
| New | +$47.8K | ﹤0.01% | 3533 |
|
|
2023
Q1 | – | Sell |
-26,592
| Closed | -$351K | – | 4012 |
|
|
2022
Q4 | $351K | Buy |
+26,592
| New | +$188K | ﹤0.01% | 2768 |
|
|
2020
Q2 | – | Sell |
-2
| Closed | -$1 | – | 4369 |
|
|
2020
Q1 | $1 | Hold |
2
| – | – | ﹤0.01% | 4313 |
|
|
2019
Q4 | $5 | Sell |
2
-14
| -88% | -$40 | ﹤0.01% | 4401 |
|
|
2019
Q3 | $54 | Hold |
16
| – | – | ﹤0.01% | 4463 |
|
|
2019
Q2 | $96 | Buy |
+16
| New | +$105 | ﹤0.01% | 4482 |
|
|
2019
Q1 | – | Sell |
-16
| Closed | -$103 | – | 4367 |
|
|
2018
Q4 | $103 | Hold |
16
| – | – | ﹤0.01% | 4176 |
|
|
2018
Q3 | $264 | Hold |
16
| – | – | ﹤0.01% | 4360 |
|
|
2018
Q2 | $332 | Sell |
16
-196
| -92% | -$4.09K | ﹤0.01% | 4338 |
|
|
2018
Q1 | $5.01K | Buy |
212
+12
| +6% | +$3.23K | ﹤0.01% | 4050 |
|
|
2017
Q4 | $37.5K | Buy |
200
+109
| +120% | +$21.9K | ﹤0.01% | 3797 |
|
|
2017
Q3 | $19.5K | Sell |
91
-6
| -6% | -$1.24K | ﹤0.01% | 3602 |
|
|
2017
Q2 | $19.8K | Buy |
97
+93
| +2,325% | +$18.3K | ﹤0.01% | 3666 |
|
|
2017
Q1 | $747 | Sell |
4
-41
| -91% | -$8.12K | ﹤0.01% | 3760 |
|
|
2016
Q4 | $11.3K | Sell |
45
-17
| -27% | -$3.86K | ﹤0.01% | 3397 |
|
|
2016
Q3 | $12.9K | Buy |
62
+34
| +121% | +$6.74K | ﹤0.01% | 3104 |
|
|
2016
Q2 | $5.74K | Buy |
+28
| New | +$4.95K | ﹤0.01% | 3208 |
|
|
2016
Q1 | – | Sell |
-76
| Closed | -$18.9K | – | 2971 |
|
|
2015
Q4 | $18.9K | Buy |
+76
| New | +$24.5K | ﹤0.01% | 3302 |
|
Other funds holding PDSB
VCM
QCM
VFT
MCM
BNP Paribas Financial Markets's PDSB Position: Q2 2026 in Review
BNP Paribas Financial Markets held its PDS Biotechnology (PDSB) position steady in Q2 2026 at 648 shares worth $571. The position accounts for ﹤0.01% of the portfolio, ranked #5667.
BNP Paribas Financial Markets first reported a position in PDSB in Q4 2015 and has held it in 30 quarters since. The position peaked at $351K in Q4 2022. 41 funds tracked by Wall St. Rank hold PDSB as of Q2 2026.
- BNP Paribas Financial Markets held 648 shares of PDS Biotechnology worth $571 as of Q2 2026.
- BNP Paribas Financial Markets left its PDS Biotechnology share count unchanged in Q2 2026.
- PDS Biotechnology made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5667 holding.
- BNP Paribas Financial Markets first reported a position in PDS Biotechnology in Q4 2015 and has held it in 30 quarters since.
- BNP Paribas Financial Markets's PDS Biotechnology position peaked at $351K in Q4 2022.
- 41 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.